Shares Up Following Orphan Drug Designation

Classification as an orphan drug incentivizes and supports the development of certain treatments, increasing access to therapies for rare diseases and providing significant benefits, including market exclusivity, regulatory assistance and financial incentives. 

Pioneering biotechnology company NurExone Biologic Inc. (TSXV: NRX) announced in a press release today that the U.S. Food and Drug Administration granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, a groundbreaking regenerative therapy for acute spinal cord injury, a condition where effective treatments are limited.

The significant development covers the use of mesenchymal stem cell (MSC) derived small extracellular vesicles (EVs) loaded with short and modified interfering RNA (siRNA) targeting the phosphatase and tensin homolog (PTEN) protein for acute spinal cord injury, as implemented in the ExoPTEN drug under development. Shares were trading at $0.315 in afternoon trade.

Copyright © 2023 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

]]>